Group items tagged

The National Health Service (NHS) on Monday launched a new national campaign to find the 'missing millions' who could be living with undiagnosed high blood pressure, often described as a 'silent killer'. People are being warned that the condition rarely has any symptoms and it can lead to fatal heart attacks, strokes, kidney disease and vascular dementia, if left untreated. According to the NHS, high blood pressure affects an estimated 32 per cent of adults and approximately three in 10 of these remain undiagnosed, equating to 4.2 million people in England. The NHS has expanded blood pressure checks in community pharmacies to include 2.5 million more tests as part of the Pharmacy First programme. With the 'Get Your Blood Pressure Checked' campaign, the health service is encouraging those aged 40 years and over to get a free blood pressure test at a participating pharmacy, for which they don't need to be booked in advance. Health Minister Andrea Leadsom expressed confidence that this new drive will help to prevent the potentially "fatal consequences" of untreated high blood pressure. She urged people to go to their local pharmacy to get their blood pressure checked, stating that it could be a "lifesaving trip."

A new study has revealed that public trust in services provided by local pharmacies ranks highest in the UK, although confidence in the NHS has nosedived following the pandemic. The 2022 Edelman Trust Barometer report published on Wednesday (April 21) found that around 78 per cent of respondents trust their local pharmacies, the highest for any provider cited in the survey. Besides, 72 per cent said pharmacists are among the most trusted to tell the truth about health matters and protect public health, almost similar to 'my doctor' (75%) and health experts (74%). Just under half of them said the pandemic has decreased their confidence that the NHS is well-equipped in handling major health crisis. The survey also revealed that 60 per cent think they lack access to high-quality healthcare.

Superdrug has announced a pay increase for newly qualified pharmacists, in a move that will see wages rise to £50,000 - ensuring that Superdrug Pharmacists continue to receive the strongest renumeration package on the high street today. Superdrug is also enhancing its patient experience and operational structure, with the introduction of a new role of Pharmacy Team Leader to selected pharmacy stores. Pharmacy Team Leaders will be dispenser trained and provide a clear line of accountability for day-to-day dispensary activity including adhering to legal and clinical frameworks whilst supporting, coaching, and developing a high-performing pharmacy team. The role also allows Superdrug to offer a clear line of progression for talented Pharmacy Dispensers and Technicians who want to do more in their career and recognises the valuable contribution Pharmacy Dispensers & Technicians play in community pharmacy. In addition, the appointment of two new Heads of Pharmacy Operations sees the high street retailer driving and improving Superdrug's pharmacy performance to offer the best possible care for patients. Craig Watt, Pharmacist and previously Area Manager, has been appointed to Head of Pharmacy Operations North and will be responsible for the operation of Superdrug's central distribution hub serving its e-pharmacy and Online Dr team.

One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.

Pharmacists working in Northern Ireland think the retention fees are too high, and most would prefer to pay in instalments, if that option is available, amid the increased living costs, a new survey has found. 97 per cent of the respondents to the survey, conducted by the Pharmacists' Defence Association (PDA) of its Northern Irish members, felt the fees were too high. Four in five said they would opt to pay in instalments if this option were available to them in light of the challenges of significant one-off payments. On average, the fees accounted for 23 per cent of a pharmacist's take-home pay for one month, and 98 per cent did not see any value added to their professional standing for the sum, according to the survey. The PDA said the respondents also reported feeling disadvantaged among their colleagues in terms of how fees are collected, with many also wondering why the registration fee was not offset for those on maternity leave or working reduced or flexible hours.

The government's 200 million dental recovery plan has come under fierce criticism from the opposition party after health minister Dame Andrea Leadsom admitted that there is a "high likelihood" that it will not deliver 2.5 million dental appointments. Published last month, the plan is aimed at ensuring easier and faster access to NHS dental care across England, with up to 1.5 million extra treatments expected to be delivered over the next 12 months. Various new measures were set out to attract new dentists, including increasing dental training places by up to 40 per cent by 2032, as part of the NHS Long Term Workforce Plan. On Tuesday, Leadsom told MPs on the Health and Social Care Committee that the figure was based on NHS modelling of a "complicated set of factors" and there is "quite a high likelihood of not being reliable as is the case with all modelling." Preeti Kaur Gill MP, shadow minister for primary care and public health, expressed shock over the admission by the public health minister that there is uncertainty regarding the plan's ability to deliver on its promises, which she said: "shows the Conservatives are out of ideas and out of time."

The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the impact that high medicine price rises are having on contractor. Recently, the Department of Health and Social Care (DHSC) has granted the final list of price concessions for December 2022. The latest additions bring the total number of concessionary prices granted for the month of December to 198, surpassing the previous record of 159 granted in September 2022. PSNC has heard from hundreds of community pharmacy contractors who are paying inflated prices for antibiotics used for the treatment of Strep A and who have rightly been concerned about the lack of certainty around the final reimbursement prices for these medicines. It added: "We welcomed the involvement of the Competition and Markets Authority (CMA) to look into the pricing of antibiotics. But the number of reports we are getting from contractors about medicines price rises are just not acceptable and this goes far beyond the antibiotic crisis."

The National Institute for Health and Care Excellence (NICE) has recommended first new treatment - 'romosozumab' for osteoporosis for over a decade. Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture are set to benefit from a new treatment - romosozumab - after NICE published the final draft guidance. Over 20,000 people could be eligible for the treatment according to the company. Clinical trial evidence showed that romosozumab (also known as EVENITY and made by UCB) followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone. Osteoporosis is a disease that causes bones to become thin and fragile. Many people with osteoporosis show no symptoms, but they may be at increased risk of fracture. Osteoporosis leads to nearly 9 million fractures around the world each year, and over 300,000 people per year attend hospitals in the UK with fractures caused by osteoporosis.

Lapses in strategies to tackle COVID-19 this year continue to create the perfect conditions for a deadly new variant to emerge, as parts of China witness a rise in infections, the head of the World Health Organization said on Friday (December 2). The comments by WHO Director-General Tedros Adhanom Ghebreyesus mark a change in tone just months after he said that the world has never been in a better position to end the pandemic. "We are much closer to being able to say that the emergency phase of the pandemic is over, but we're not there yet," Tedros said on Friday. The global health agency estimates that about 90% of the world's population now has some level of immunity to SARS-COV-2 either due to prior infection or vaccination. "Gaps in testing … and vaccination are continuing to create the perfect conditions for a new variant of concern to emerge that could cause significant mortality," Tedros said. COVID-19 infections are at record highs in China and have started to rise in parts of Britain after months of decline.

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."

Charac, an NHS-integrated one-stop platform for independent community pharmacies, and Positive Solutions, the fastest growing pharmacy IT provider in the UK, have agreed on a collaboration to support community pharmacies through new integrated technology platform - MyHealthHub. The tech platform aims to give pharmacies a powerful and compelling tool to both help retain and attract new patients. The app will also allow the over 7,200 independent high street pharmacies which are lacking a digital footprint to compete with larger online pharmacies by providing them with an online presence. The long-term strategic partnership brings together Charac's innovative approach to patient relationship management and Positive Solutions trusted expertise in digital solutions for pharmacy. With Positive Solutions' Analyst PMR used daily by 16,000 pharmacy team members to process over 87 million scripts and 180 million items, the collaboration will help transform patient engagement and continue driving service business to pharmacies across the UK using a new innovative, integrative technology platform, MyHealthHub. MyHealthHub will not only integrate with Analyst PMR, but also forms part of an entire new technology ecosystem from Positive Solutions, the Hx platform and will be entirely interoperable.

Superdrug, one of the leading health and beauty retailers, is all set to invest in 25 new stores this year, expanding its bricks-and-mortar retail footprint. It confirmed with Pharmacy Business that amongst its 25 new stores there "will be a mix of pharmacy and retail stores". The venture is expected to create over 570 jobs nationwide, creating a seamless customer experience and providing vital support for high streets and local communities. The investment, part of the brand's O+O (Online + Offline) platform strategy to deliver its omnichannel ambitions, is driven by continued strong performance figures. In Q4 2022 Superdrug reported increased volume and value sales and footfall across both sides of the beauty and health business. Whilst in 2021 revenue rose 5.1% to £1,168million with a profit before tax increase of 141.3%. The investment strategy has already seen Superdrug open new stores in Washington Gallery and Falkirk Retail Parks in February 2023 and in Braehead, the largest Superdrug in Scotland, just last month.

The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British Pharmaceutical Industry. BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the UK being deferred. Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.

The new data from NHS England has revealed that more than 100,000 patients were treated for minor illness by their high street pharmacist in just one month. According to new NHS figures, in June, 118,123 people with minor illnesses such as a sore throat or constipation, or those in need of medicine urgently, received a same-day consultation with their local pharmacist after calling NHS 111 or their GP practice - an increase of more than four-fifths (83%) on the number in the same month last year (64,512). The data comes alongside expanded roles for community pharmacies ahead of winter, announced at the NHS England board meeting today. "From this week, NHS 111 online can directly refer people to their high street pharmacist for a same-day consultation, rather than patients needing to call the phone line," said NHS England. Amanda Pritchard, NHS chief executive, said: "Our local pharmacies ensure hundreds of thousands of people every week get the support and medication they need and today's figures show that in just one month, over 100,000 patients have also had consultations with their local pharmacist for minor illnesses - this means patients are getting the care they need quickly but also in a convenient way that can fit in with their busy lives.

AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company's oncology portfolio. Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of genetically mutated early-stage breast cancer. The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies. Enhertu - developed jointly with Japan's Daiichi Sankyo (4568.T) - was the other drug that was endorsed by the European Medicines Agency for treating an aggressive form of breast cancer characterised by a high rate of HER2.

The Health and Social Care Secretary Steve Barclay has proposed a new £30 million fund to speed up the adoption of innovative medical technology in the NHS. He confirmed the plan today at the Conservative Party Conference 2023 in Manchester. Mr Barclay said that virtual wards will help healthcare professionals embrace new technology to improve patient care. He said: "It is vital that clinicians have access to the latest technology to save staff time, deliver high-quality care and help cut waiting lists - one of the government's top five priorities. "This investment will see the latest tech innovations rolled out across the NHS. From virtual ward beds to wearable medical devices, patients will be better supported, and we will ease pressures on hospitals this winter. "We're preparing for this winter earlier than ever before including delivering thousands more hospital beds and hundreds of new ambulances."

Boots UK to offer a free health MOT for over 40s in England between 1st April until 30th June to help eligible patients identify and take the right steps to address high blood pressure and the potential for increased risk of other health conditions. The Free Health MOT will give over 40s the information needed for them to take actions to support their overall health. It consists of a 15-minute appointment with a Boots pharmacist, during which they will receive- the NHS Blood Pressure Check Service, with GP referral if needed; optional BMI (Body Mass Index) and waist circumference measurement; lifestyle guidance on exercise, nutrition, sleep, mental wellbeing and stopping smoking; and personalised advice and recommendations . At the end of their appointment, patients will receive a booklet containing information about how to lead a healthy lifestyle and a section with the results of their MOT recorded. Claire Nevinson, Superintendent Pharmacist at Boots, said: "The Free Health MOT at Boots is intended to help people gain greater insight into their health and take the steps they need to improve it. As we get older, we become more vulnerable to conditions like high blood pressure, so it's important that we take steps to help stay healthy. The checks done during the MOT and the advice provided not only helps individual patients lead healthier lives but also reduces pressure on the NHS by offering accessible care in pharmacies at the heart of communities." The availability of appointments for a Free Health MOT at Boots comes at a time when new research indicates people want to lead healthier lives.

NHS England has launched a cloud-based platform that links recently-retired consultants, who still hold a licence to practice, with secondary care providers who need additional help with their waiting lists. It has been developed to make it easier and more flexible for retired doctors to return to the health service as part of the Long Term Workforce Plan. NHS chief executive Amanda Pritchard in June 2023 announced the NHS Emeritus pilot scheme, which is expected to help reduce long waits for elective care. Initially, the scheme will run for a year across England, and if successful, it may be expanded to cover other work areas. Health Minister Andrew Stephenson commented: "Returning consultants will bring invaluable experience and knowledge, and the new digital platform will match highly-skilled consultants with the NHS trusts that require their expertise, providing high quality care and alleviating pressures on high demand areas.

NEW YORK (Reuters Health) - Men who want to keep their bones strong may want to add running to their exercise routine, new research suggests. In a study of 42 athletic men ages 19 to 45, researchers found that running seemed to have even bigger benefits for bone mass than strength training did. Both runners and weight trainers had greater bone density in the spine compared with road cyclists, but much of the benefit in weight trainers seemed to stem from their greater muscle mass.

Online pharmacy PillTime has taken a step to boost its prescription growth by implementing new Patient Medication Record (PMR) system Titan in its state-of-the-art premises. PillTime moved to new, expanded 26,000sqft premises in Cribbs Causeway on the edge of Bristol earlier this year, where it has also installed state-of-the-art robotics in a bid to significantly enhance future productivity and capacity. Teething problems over Easter weekend saw PillTime struggling to seamlessly integrate all the new systems and processes while physically moving premises which affected service delivery and customer support. However, CEO Leighton Humphreys was supported by Tariq Muhammad, CEO of Invatech Health, who is a former community pharmacist and has worked with independent pharmacies around the UK as well as larger online businesses, to integrate Titan into their workflows. Alongside integration work, Muhammad and his team supported PillTime with necessary design, governance and pharmacy expertise as the company struggled to meet its usual high standards for dispensing medicines to patients.